• 317 Citations
  • 12 h-Index
20062020
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

Research Expertise:
Pharmacology | Neuroscience | Biochemistry

I am interested in developing new medications for neuropsychiatric disorders, including Alzheimer’s disease, schizophrenia, ADHD, pain, anxiety, and a particular interest in drug addiction. My lab works closely with medicinal chemists to design and test new drug-like molecules, combining molecular and behavioral pharmacology methods to evaluate the preclinical potential of new compounds designed to target the dopamine D4 receptor, the µ opioid receptor, and the trace amine-associated receptor 1, among others.

Honors and Awards:
2017 Maharaj Ticku Memorial Travel Fellowship for New Investigators Award, Behavior, Biology and Chemistry Conf.
2015 Frances R. Lax Faculty Development Award, Rowan University
2013 Mentoring Award for Fellows, NIDA-IRP, NIH
2013 Postdoctoral Mentor Award, NIH
2012 & 2013 Fellows’ Award for Research Excellence, NIH

Member of:
American Society for Pharmacology and Experimental Therapeutics https://www.aspet.org/
Pharmacology Society (Councilor) https://www.aspet.org/MAPS/
Philadelphia Chapter of the Society for Neuroscience http://pcsfn.com/

Education/Academic qualification

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Dopamine D3 Receptors Medicine & Life Sciences
Ligands Medicine & Life Sciences
Metabotropic Glutamate 5 Receptor Medicine & Life Sciences
Substance-Related Disorders Medicine & Life Sciences
Dopamine Antagonists Medicine & Life Sciences
eticlopride Medicine & Life Sciences
Self Administration Medicine & Life Sciences
Cocaine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2017 2020

Research Output 2006 2019

  • 317 Citations
  • 12 h-Index
  • 19 Article
  • 2 Chapter

Dopamine D 4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy

Keck, T., Free, R. B., Day, M. M., Brown, S. L., Maddaluna, M. S., Fountain, G., Cooper, C., Fallon, B., Holmes, M., Stang, C. T., Burkhardt, R., Bonifazi, A., Ellenberger, M. P., Newman, A. H., Sibley, D. R., Wu, C. & Boateng, C. A., Apr 11 2019, In : Journal of Medicinal Chemistry. 62, 7, p. 3722-3740 19 p.

Rowan University

Research output: Contribution to journalArticle

Open Access
Structure-Activity Relationship
Dopamine
Ligands
2-(3',4',5',6'-tetrahydro-2'H-(2,4') bipyridinyl-1'-yl)-N-m-tolyl-acetamide
Arrestin

Multitarget 1,4-Dioxane Compounds Combining Favorable D 2 -like and 5-HT 1A Receptor Interactions with Potential for the Treatment of Parkinson's Disease or Schizophrenia

Del Bello, F., Ambrosini, D., Bonifazi, A., Newman, A. H., Keck, T., Giannella, M., Giorgioni, G., Piergentili, A., Cappellacci, L., Cilia, A., Franchini, S. & Quaglia, W., May 15 2019, In : ACS Chemical Neuroscience. 10, 5, p. 2222-2228 7 p.

Rowan University

Research output: Contribution to journalArticle

Receptor, Serotonin, 5-HT1A
Parkinson Disease
Serotonin
Schizophrenia
Derivatives
14 Citations (Scopus)

Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R)

Kumar, V., Moritz, A. E., Keck, T., Bonifazi, A., Ellenberger, M. P., Sibley, C. D., Free, R. B., Shi, L., Lane, J. R., Sibley, D. R. & Newman, A. H., Feb 23 2017, In : Journal of Medicinal Chemistry. 60, 4, p. 1478-1494 17 p.

Rowan University

Research output: Contribution to journalArticle

Dopamine D3 Receptors
Pharmacology
Ligands
Pharmaceutical Preparations
1H-indole-2-carboxylic acid (4-(2-(cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl)cyclohexyl)amide
8 Citations (Scopus)

The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1Areceptor over α1-adrenoceptor and D2-like receptor subtypes

Del Bello, F., Bonifazi, A., Giannella, M., Giorgioni, G., Piergentili, A., Petrelli, R., Cifani, C., Micioni Di Bonaventura, M. V., Keck, T., Mazzolari, A., Vistoli, G., Cilia, A., Poggesi, E., Matucci, R. & Quaglia, W., Jan 1 2017, In : European Journal of Medicinal Chemistry. 125, p. 233-244 12 p.

Rowan University

Research output: Contribution to journalArticle

Adrenergic Receptors
Amines
Ligands
Anxiety
Retrospective Studies
8 Citations (Scopus)

Toward understanding the structural basis of partial agonism at the dopamine D3 receptor

Michino, M., Boateng, C. A., Donthamsetti, P., Yano, H., Bakare, O. M., Bonifazi, A., Ellenberger, M. P., Keck, T., Kumar, V., Zhu, C., Verma, R., Deschamps, J. R., Javitch, J. A., Newman, A. H. & Shi, L., Jan 26 2017, In : Journal of Medicinal Chemistry. 60, 2, p. 580-593 14 p.

Rowan University

Research output: Contribution to journalArticle

Dopamine D3 Receptors
Stereoisomerism
Molecular Dynamics Simulation
Substance-Related Disorders
Binding Sites

Press/Media

Government-Owned Inventions; Availability for Licensing

Thomas Keck

11/20/13

1 item of media coverage

Rowan University

Press/Media: Press / Media